---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-005322"
form_type: "8-K"
ticker: "PROF"
cik: "0001628808"
company_name: "Profound Medical Corp."
filed_at: "2026-08-06T20:20:20+00:00"
generated_at: "2026-08-06T20:21:44.958733+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Profound Medical Q2 revenue $2.5M (+12% YoY); net loss improves 39% to $9.5M; reiterates FY2026 guidance of $25M

## Summary
- Revenue $2.5M, up 12% YoY; $3.1M of TULSA shipments shifted to Q3 due to logistics, resolved.
- Net loss $9.5M ($0.26/share) vs $15.7M ($0.52/share) in Q2 2025, a 39% improvement.
- Gross margin 78% (up from 73%); operating expenses down 16% to $13.0M.
- Reiterates FY2026 revenue guidance of $25.0M (56% YoY growth) and gross margin ≥70%.
- TULSA-PRO installed base 84; payer coverage expanded by 18.3M lives; first employer health plans list TULSA.

## SEC filing metadata
- accession: 0001171843-26-005322
- form_type: 8-K
- ticker: PROF
- cik: 0001628808
- company_name: Profound Medical Corp.
- filed_at: 2026-08-06T20:20:20+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628808/000117184326005322/0001171843-26-005322-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628808/000117184326005322/f8k_080626.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-005322
- JSON: https://secwatch.observer/filing/0001171843-26-005322.json
- Plain text: https://secwatch.observer/filing/0001171843-26-005322.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.